Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06031285
Status:
RECRUITING
Last Update Posted:
2023-09-11
First Post:
2023-09-04
Brief Title:
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT A Phase-2 Clinical Trial
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Perioperative Sintilimab Plus Bevacizumab Biosimilar and Transarterial Embolization Hepatic Artery Infusion Chemotherapy TACE-HAIC for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus PVTT A Phase-2 Clinical Trial
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Although resection provided survival benefit for selected HCC patients with PVTT the recurrence rate is still high for those patients It is still unknown whether perioperative Sintilimab a PD-1antibody plus bevacizumab biosimilar and TACE-HAIC will improve the survival for those patients We initialed this phase 2 clinical trial to prove the perioperative therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None